Genetic polymorphism of XRCC1 correlated with response to oxaliplatin-based chemotherapy in advanced colorectal cancer

Pathology and Oncology Research

Volumn 18, Issue 4, 2012, Pages 1009-1014

  Lv, Hongying ^a   Li, Qicai ^a   Qiu, Wengsheng ^a   Xiang, Jinyu ^a   Wei, Hongjun ^b   Liang, Hua ^c   Sui, Aihua ^a   Liang, Jun ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^b QINGDAO MUNICIPAL HOSPITAL   (China)

^c Department of Oncology   (China)

Author keywords

Colorectal neoplasms genetics; Oxaliplatin drug therapy; Polymorphism; X ray repair cross complementing 1 genetics

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; XRCC1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOSENSITIVITY; CHINESE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHARMACOGENETICS; X RAY REPAIR CROSS COMPLEMENTING 1 GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, SINGLE NUCLEOTIDE; SURVIVAL ANALYSIS;

EID: 84868476128     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9536-6     Document Type: Article

References (17)

1. Pisani P, Parkin DM, Bray F, Ferlay J (1999) Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83 (1):18-29. doi:10.1002/(SICI)1097-0215(19990924)83:1<18:: AID-IJC5>3.0.CO;2-M
2. Faivre S, Chan D, Salinas R, Woynarowska B, Woynarowski JM (2003) DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol 66(2):225-237
3. Lentz F, Tran A, Rey E, Pons G, Treluyer JM (2005) Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics 5(1):21-33
4. Kang D (2003) Genetic polymorphisms and cancer susceptibility of breast cancer in Korean women. J Biochem Mol Biol 36(1):28-34
5. Friedberg EC (2001) How nucleotide excision repair protects against cancer. Nat Rev Cancer 1(1):22-33. doi:10.1038/35094000
6. Tian M, Shinkura R, Shinkura N, Alt FW (2004) Growth retardation, early death, and DNA repair defects inmice deficient for the nucleotide excision repair enzyme XPF. Mol Cell Biol 24(3):1200-1205
7. Mort R,Mo L, McEwan C, MeltonDW(2003) Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer 89(2):333-337. doi:10.1038/sj.bjc.6601061
8. Motycka TA, Bessho T, Post SM, Sung P, Tomkinson AE (2004) Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52. J Biol Chem 279(14):13634-13639. doi:10.1074/jbc.M313779200
9. Nagasubramanian R, Innocenti F, Ratain MJ (2003) Pharmacogenetics in cancer treatment. Annu Rev Med 54:437-452. doi:10.1146/annurev.med.54.101601. 152352
10. Chacko P, Rajan B, Joseph T, Mathew BS, Pillai MR (2005) Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer. Breast Cancer Res Treat 89(1):15-21. doi:10.1007/s10549-004-1004-x
11. Kiyohara C, Takayama K, Nakanishi Y (2006) Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer 54(3):267-283. doi:10.1016/j.lungcan.2006.08.009
12. Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW (2006) XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 15(12):2384-2390. doi:10.1158/1055-9965.EPI-06-0381
13. Zhang Z, Miao XP, Tan W, Guo YL, Zhang XM, Lin DX (2006) Correlation of genetic polymorphisms in DNA repair genes ADPRT and XRCC1 to risk of gastric cancer. Ai Zheng 25(1):7-10
14. Kim DY, Kim YB, Choi HS, Kim JM, Suh K (2006) Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, MTHFR or XRCC1 gene? Ann Surg Oncol 13(2):7-7
15. Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, Lenz HJ (2001) A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 21(4B):3075-3079
16. Liu B,Wei J, Zou Z, Qian X, Nakamura T, ZhangW, Ding Y, Feng J, Yu L (2007) Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. Eur J Hum Genet 15(10):1049-1053. doi:10.1038/sj.ejhg.5201884
17. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC (2004) XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 22(13):2594-2601. doi:10.1200/JCO.2004.08. 067JCO. 2004.08.067